Skip to main content
NIH funding notice PAR-25-352

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Open. Closes October 25, 2027.

Posted
January 15, 2025
Close date
October 25, 2027
Activity codes
U01
Institutes taking part
NIMH

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

  1. Reissues: PAR-22-143 National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)
  2. 2 steps back: PAR-20-118 National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)
  3. 3 steps back: PAR-18-230 National Cooperative Drug/Device Discovery/Development Groups (U01 Clinical Trial Optional)
  4. 4 steps back: PAR-17-185 National Cooperative Drug/Device Discovery/Development Groups (U01)
  5. 5 steps back: PAR-14-184 National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01)

Who won it before

4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,989,144 in first-year total cost, median $1,554,044.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-B (04)]1
  2. Special Emphasis Panel[ZMH1 ERB-C (04)]1
  3. Special Emphasis Panel[ZMH1 ERB-C (05)]1
  4. Special Emphasis Panel[ZMH1 ERB-R (02)]1

Most frequent institutions

  1. YALE UNIVERSITY2
  2. MOLECULAR NEUROIMAGING, LLC1
  3. UNIVERSITY OF FLORIDA1
Competing awards under PAR-25-352 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Preclinical development of a precision therapy for a monogenic mental health disorder1U01MH136567-01 · under PAR-22-143KAMENECKA, THEODORE MMILLER, COURTNEY ARUMBAUGH, GAVIN RUNIVERSITY OF FLORIDA, FL$1,524,504ZMH1
2022A Program for Innovative PET Radioligand Development and Application - A Translational Toolbox for Treatments for Mental Health2U01MH107803-06 · under PAR-20-118CARSON, RICHARD E.HUANG, YIYUN HENRYYALE UNIVERSITY, CT$1,583,584ZMH1
2019A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia1U01MH121766-01 · under PAR-18-230ANTICEVIC, ALANKRYSTAL, JOHN H.YALE UNIVERSITY, CT$3,804,360ZMH1
2015A Program for Innovative PET Radioligand Development and Application - a translational toolbox for treatments for Mental Health1U01MH107803-01 · under PAR-14-184TAMAGNAN, GILLES DMOLECULAR NEUROIMAGING, LLC, CT$1,076,696ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.